Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;9(6):4280-4290.
doi: 10.1002/ehf2.14164. Epub 2022 Sep 20.

An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction

Affiliations

An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction

Hong Yang et al. ESC Heart Fail. 2022 Dec.

Abstract

Aims: Transthyretin cardiac amyloidosis (ATTR-CA) has been realized as an important cause of heart failure with preserved ejection fraction (HFpEF). We aim to provide insights into its prevalence in Chinese HFpEF patients, which is not known to date, using increased wall thickness (IWT) score by echocardiography.

Methods: Consecutive patients with HFpEF (EF ≥ 40%) and IWT (≥12 mm) were prospectively screened. Echocardiography was performed, and the IWT score incorporated relative wall thickness, E/e' ratio, longitudinal strains, and tricuspid annular plane systolic excursion, and septal apical-to-base ratio was calculated. ATTR-CA was defined as score ≥8 in the absence of serum and urine free light chain.

Results: Six hundred twenty-four HFpEF patients from January 2019 to December 2021 were enrolled, of which 65.2% were males and the median (interquartile range [IQR]) age was 66 (IQR 57, 73) years. Thirty-three patients (5.3%, 95% CI 3.5-7.0%) were with score ≥8, and 33.3% were females. They were younger (58 vs. 69 years, P < 0.001), had higher NT-proBNP (6525.0 vs. 1741.5 pg/mL, P < 0.001) and troponin I (105.2 vs. 27.7 pg/mL, P = 0.001) level, and lower LVEF (47% vs. 57%, P < 0.001) compared with the patients with score <5. In the internal cohort (82 patients) who had undergone scintigraphy, the IWT score ≥8 was shown to have a sensitivity of 85.7% (95% CI 56.2-97.5%) and a specificity of 92.6% (95% CI 83.0-97.3%) for diagnosing CA, and the IWT score <5 had great accuracy in excluding CA with the negative predictive value of 100%, supporting the clinical usefulness of the IWT score to guide further dedicated testing for ATTR-CA.

Conclusions: The IWT score by echocardiography was an excellent tool for screening ATTR-CA in HFpEF. In Chinese HFpEF patients associated with a hypertrophic phenotype, the proportion of highly suspected ATTR-CA as detected by IWT score ≥8 was 5.3%, lower than the reported prevalence of ATTR-CA in non-Asian patients with the disease.

Keywords: 99mTc-pyrophosphate scintigraphy; Heart failure with preserved ejection fraction; Multi-parametric echocardiography score; Transthyretin amyloid cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Flow chart for study design, patient inclusion, and group classification by the IWT score.
Figure 2
Figure 2
The validation cohort that was consisted of 82 patients who underwent scintigraphy and the patients' classification by the IWT score and the result of scintigraphy.
Figure 3
Figure 3
A HFpEF patients with the IWT score = 9 and a positive 99mTc‐PYP scintigraphy. (A) 99mTc‐PYP SPECT and (B) 99mTc‐PYP SPECT/CT (grade 3 radiotracer uptake on the Perugini scale at 1 and 3 h and 1‐h heart‐to‐lung ratio of 1.72 and 3 h of 1.77). (C) A “bull's‐eye” presentation of LV longitudinal strains by TTE showing typical apical sparing pattern and low longitudinal strains (3.2%). (D) Doppler was restrictive with the E/e′ ratio of 35.07. (E) TTE (four‐chamber view) showed left ventricular hypertrophy. (F) ECG presented atrial fibrillation and pacemaker rhythm. CT, computed tomography.

References

    1. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018; 6: 678–685. - PMC - PubMed
    1. Yoon S, Eom GH. Heart failure with preserved ejection fraction: Present status and future directions. Exp Mol Med. 2019; 51: 1–9. - PMC - PubMed
    1. Gonzalez‐Lopez E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐Del Moral FJ, Cobo‐Marcos M, Robles C, Bornstein B, Salas C, Lara‐Pezzi E, Alonso‐Pulpon L, Garcia‐Pavia P. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36: 2585–2594. - PubMed
    1. Lo Presti S, Horvath SA, Mihos CG, Rajadhyaksha C, McCloskey V, Santana O. Transthyretin cardiac amyloidosis as diagnosed by 99mTc‐PYP scanning in patients with acute heart failure and preserved ejection fraction. Crit Pathw Cardiol. 2019; 18: 195–199. - PubMed
    1. Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020; 8: 712–724. - PMC - PubMed